Dr. Joan Fallon, Founder and CEO of Curemark, is considered a visionary scientist, champion and advocate for the health and well-being of children worldwide. Curemark is focused on the development of novel therapies to treat diseases for which there are no or limited treatments. Curemark’s first drug CM-AT is targeted to treat autism and is still in clinical trials. CM-AT has received Fast Track status from the FDA. Joan holds over 200 patents worldwide. She served on the ADA Board of Advisors for the new Yankee Stadium. She holds appointments as a Senior Advisor to the Henry Crown Fellows at The Aspen Institute, is a Distinguished Fellow at the Athena Center for Leadership at Barnard College. She is a board member of DREAM the charter school in Harlem, formerly known as Harlem RBI. She is a proud alumna and Trustee of Franklin & Marshall College. In 2017, Joan was named EY Entrepreneur of The Year NY in Healthcare and in 2018, she received the Creative Entrepreneurship Award by The New York Hall of Science.